Analysis

Shkreli's Brazen Defiance May Lead To Harsher Sentence

Law360, New York (August 7, 2017, 9:06 PM EDT) -- Public statements from former Turing Pharmaceuticals and Retrophin CEO Martin Shkreli deriding the prosecution’s securities fraud case against him may come back to bite him at sentencing, legal experts said Monday.

Shkreli has not shied from the spotlight since his conviction Friday on two counts of securities fraud and another conspiracy charge. He has accused prosecutors of leading a “witch hunt,” and told his followers on social media that the government had “concocted a fantasy world of eight criminal counts connecting nonexistent dots into an elaborate conspiracy.”

Prosecutors claimed Shkreli defrauded investors in his MSMB Capital and MSMB Healthcare hedge funds,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS